Investors

Key press releases

25 Jun 2026
16:30 E.S.T.

Cellectis Reports Results from Shareholders Meeting Held on June 25, 2026

11 Jun 2026
02:40 E.S.T.

Cellectis Presents Final Phase 1 Results of Lasme-cel and Preliminary Results on Eti-cel at EHA 2026 Congress

09 Jun 2026
16:30 E.S.T.

Cellectis Receives FDA RMAT Designation for lasme-cel, the First Allogeneic CAR-T Therapy in a Pivotal Trial for Patients with r/r B-ALL

Key upcoming events

15 Sep 2026

2026 Baird’s Global Healthcare Conference

Learn more

Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on the Euronext Growth Paris (ticker: ALCLS).

$2.8100

-0.0650 (-2.2609%)

Prev. close: 2.8750
Volume: 9,181
High: 2.8700
Capitalization: 202.583M

€2.4120

-0.0220 (-0.9039%)

Prev. close: 2.4340
Volume: 153,735
High: 2.4620
Capitalization: 173.890M

See stock information

Covering research analysts

Barclays - Etzer Darout

Bryan Garnier - Oscar Haffen-Lamm

Citizens Bank - Silvan Tuerkcan

Clear Street - Bill Maughan

Goldman Sachs - Salveen Richter

Jefferies - Amin Makarem

Kempen - Sebastiaan van der Schoot

Oddo BHF - Martial Descoutures

RW Baird - Jack Allen

Wells Fargo – Yanan Zhu

Cellectis contact information

Arthur Stril, Chief Financial Officer & Chief Business Officer

investors@cellectis.com

Citibank ADR contact information

Intermediaries & Investors
US: +1 212 723 5435
UK: +44 207 500 2030

citiadr@citi.com

Société Générale Securities Services - Ordinary Shares contact information

Call center in English and French

Monday to Friday from 8:30am to 6pm CEST

+33 (0)2 51 85 67 89